文献速递肝病消化道肿瘤与早癌

CRKL通过介导肿瘤相关中性粒细胞浸润决定肝细胞癌抗PD-1耐药

CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2024-02-23

该研究旨在揭示肝细胞癌(HCC)抗PD-1治疗耐药机制,通过RNA测序10例接受抗PD-1治疗的患者标本及404例组织芯片免疫组化,并结合转基因小鼠模型,发现CRKL过表达通过β-catenin/VEGFα和CXCL1轴招募PD-L1+肿瘤相关中性粒细胞、抑制CD8+ T细胞功能,从而削弱抗PD-1疗效;靶向CRKL可恢复治疗敏感性。

要点

  • CRKL过表达通过动员PD-L1+肿瘤相关中性粒细胞抑制CD8+ T细胞,导致抗PD-1耐药。
  • CRKL竞争性减少Axin1与APC结合,抑制β-catenin降解,促进VEGFα和CXCL1表达。
  • 敲除CRKL或靶向其下游调控因子可恢复小鼠模型抗PD-1疗效。

核心结论

  • CRKL/β-catenin/VEGFα和CXCL1轴激活是抗PD-1治疗成功的关键障碍,CRKL抑制剂联合抗PD-1可能用于HCC治疗。

研究设计与样本

  • 对10例接受抗PD-1治疗的HCC患者标本进行RNA测序以筛选耐药基因。
  • 对404例HCC组织芯片样本进行免疫组化分析。
  • 使用Alb-Cre/Trp53fl/fl转基因小鼠经水动力尾静脉注射CRKL过表达载体构建模型。
  • 采用飞行时间质谱流式技术分析小鼠肿瘤组织免疫细胞谱系。

主要发现

  • CRKL被鉴定为抗PD-1耐药候选基因,其过表达通过动员肿瘤相关中性粒细胞(TANs)阻断CD8+ T细胞浸润和功能,从而抵消抗PD-1疗效。
  • PD-L1+ TANs是受CRKL表达调控的关键TAN亚群,呈免疫抑制表型。
  • 机制上CRKL竞争性减少Axin1结合,抑制APC介导的β-catenin蛋白酶体降解,促进VEGFα和CXCL1表达。
  • 人HCC样本验证了CRKL/β-catenin/VEGFα与CXCL1的正相关性。
  • CRISPR-Cas9敲除CRKL或靶向其下游调控因子在原位小鼠模型和患者来源类器官肿瘤球模型中有效恢复抗PD-1疗效。

临床怎么用

  • CRKL高表达可能作为HCC抗PD-1治疗耐药的潜在生物标志物。
  • CRKL抑制剂联合抗PD-1治疗可能成为HCC治疗新策略。
  • 研究结果支持基于贝伐珠单抗的免疫检查点抑制剂联合治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in resistance to anti-PD-1 therapy in HCC. METHODS: Gene expression in HCC specimens from 10 patients receiving anti-PD-1 therapy was identified by RNA-sequencing. A total of 404 HCC samples from tissue microarrays were analyzed by immunohistochemistry. Transgenic mice (Alb-Cre/Trp53fl/fl) received hydrodynamic tail vein injections of a CRKL-overexpressing vector. Mass cytometry by time of flight was used to profile the proportion and status of different immune cell lineages in the mouse tumor tissues. RESULTS: CRKL was identified as a candidate anti-PD-1-resistance gene using a pooled genetic screen. CRKL overexpression nullifies anti-PD-1 treatment efficacy by mobilizing tumor-associated neutrophils (TANs), which block the infiltration and function of CD8+ T cells. PD-L1+ TANs were found to be an essential subset of TANs that were regulated by CRKL expression and display an immunosuppressive phenotype. Mechanistically, CRKL inhibits APC (adenomatous polyposis coli)-mediated proteasomal degradation of β-catenin by competitively decreasing Axin1 binding, and thus promotes VEGFα and CXCL1 expression. Using human HCC samples, we verified the positive correlations of CRKL/β-catenin/VEGFα and CXCL1. Targeting CRKL using CRISPR-Cas9 gene editing (CRKL knockout) or its downstream regulators effectively restored the efficacy of anti-PD-1 therapy in an orthotopic mouse model and a patient-derived organotypic tumor spheroid model. CONCLUSIONS: Activation of the CRKL/β-catenin/VEGFα and CXCL1 axis is a critical obstacle to successful anti-PD-1 therapy. Therefore, CRKL inhibitors combined with anti-PD-1 could be useful for the treatment of HCC. IMPACT AND IMPLICATIONS: Here, we found that CRKL was overexpressed in anti-PD-1-resistant hepatocellular carcinoma (HCC) and that CRKL upregulation promotes anti-PD-1 resistance in HCC. We identified that upregulation of the CRKL/β-catenin/VEGFα and CXCL1 axis contributes to anti-PD-1 tolerance by promoting infiltration of tumor-associated neutrophils. These findings support the strategy of bevacizumab-based immune checkpoint inhibitor combination therapy, and CRKL inhibitors combined with anti-PD-1 therapy may be developed for the treatment of HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Xie P, Yu M, Zhang B, et al. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. J Hepatol. 2024. PMID: 38403027. doi:10.1016/j.jhep.2024.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。